Skip to main content

Ravulizumab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial

In brief

Ravulizumab lowers urinary protein by 43% versus placebo at 34 weeks

In an interim analysis of 352 adults with IgA nephropathy, urinary protein fell 46.6% with ravulizumab and 5.6% with placebo, leaving levels 43.4% lower with the drug at week 34. Serious adverse events were less frequent with ravulizumab, and no meningococcal infections or deaths occurred; whether the protein reduction leads to lasting kidney benefit remains unknown.

Journal
The New England journal of medicine (Q1)
Published
23 October 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Jonathan Barratt, Youssef M K Farag, Kara Rice, Tobin J Cammett, Lesley A Inker, Hernán Trimarchi, et al.
PMID
42912700
DOI
10.1056/NEJMoa2607544

Why clinicians should know about it

  • Picked for Nephrology (top studies of the week, 22 November 2026): Phase 3 trial of complement inhibition in IgA nephropathy

Abstract

BACKGROUND: In patients with IgA nephropathy, complement activation drives glomerular inflammation, which leads to hematuria, proteinuria, and nephron loss. Ravulizumab is a terminal complement inhibitor that prevents formation of C5a and C5b-9. METHODS: In this phase 3 trial, we enrolled adults with IgA nephropathy who had an estimated glomerular filtration rate of at least 30 ml per minute per 1.73 m2 of body-surface area and proteinuria (24-hour urinary protein-to-creatinine ratio [with protein and creatinine both measured in grams] of ≥0.75 or total urinary protein excretion of ≥1.0 g per day), despite standard therapy. Patients were randomly assigned in a 1:1 ratio to receive an intravenous infusion of either ravulizumab or placebo every 8 weeks. In the prespecified interim analysis, the primary efficacy end point was the change from baseline in the 24-hour urinary protein-to-creatinine ratio at week 34. Safety was also assessed. RESULTS: In all, 485 patients underwent randomization, with 240 patients assigned to the ravulizumab group and 245 to the placebo group; 352 patients (176 in each group) were included in the interim analysis. In the ravulizumab group, the geometric mean 24-hour urinary protein-to-creatinine ratio at baseline and at week 34 was 1.56 and 0.83, respectively; in the placebo group, it was 1.60 and 1.48, respectively. At week 34, a significant reduction in the geometric mean 24-hour urinary protein-to-creatinine ratio was observed with ravulizumab (-46.6%) as compared with the reduction observed with placebo (-5.6%), corresponding to an adjusted geometric mean 24-hour urinary protein-to-creatinine ratio that was 43.4% (99% confidence interval, 30.1 to 54.2) lower with ravulizumab than with placebo (P<0.001). Adverse events occurred in 69.5% of the patients receiving ravulizumab and in 75.8% of those receiving placebo; serious adverse events occurred in 4.6% and 9.0%, respectively. No meningococcal infections or deaths occurred. CONCLUSIONS: In adults with IgA nephropathy, ravulizumab resulted in a significantly greater reduction in the protein-to-creatinine ratio than placebo at week 34. (Funded by Alexion, AstraZeneca Rare Disease Unit; I CAN ClinicalTrials.gov number, NCT06291376; EU Clinical Trials number, 2023-507851-31-00.).

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.